Literature DB >> 22424948

Randomized controlled trial of early parenteral nutrition cycling to prevent cholestasis in very low birth weight infants.

Agnes Salvador1, Michael Janeczko, Rachel Porat, Romal Sekhon, Anja Moewes, David Schutzman.   

Abstract

OBJECTIVES: To compare the incidence of cholestasis in very low birth weight infants receiving cycled versus continuous parenteral nutrition, and to determine factors that predispose to parenteral nutrition-associated cholestasis (PNAC). STUDY
DESIGN: Preterm infants weighing ≤ 1250 g (n = 70) at birth were randomly assigned within the first 5 postnatal days to either cycle (n = 34) or continuous (n = 36) parenteral nutrition. Liver function tests were obtained at baseline, and sequentially thereafter. Cholestasis was defined as direct bilirubin >2 mg/dL. Infants with major congenital anomalies, congenital hepatic disease, clinically apparent congenital viral infection, and those who required major abdominal surgery were excluded.
RESULTS: The incidence of PNAC was similar in the 2 groups (cycle 32% vs continuous 31%; P = 1.0). Bilirubin and transaminases were similar in both groups by repeated measures of ANOVA. Gestational age, birth weight, and Apgar scores were significantly lower, and Clinical Risk Index for Babies II scores were significantly higher in infants who developed PNAC. Using backward selection logistic regression, bronchopulmonary dysplasia, duration of parenteral nutrition, and days to full enteral nutrition emerged as factors independently associated with PNAC.
CONCLUSIONS: Early prophylactic parenteral nutrition cycling in very low birth weight infants in this study did not reduce cholestasis. Time to full feedings is a significant predictor for PNAC in very low birth weight infants. Preterm infants with bronchopulmonary dysplasia are more likely to have PNAC as a comorbidity. The Clinical Risk Index for Babies II score may help identify those preterm infants who might benefit from future prospective prevention trials.
Copyright © 2012 Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22424948     DOI: 10.1016/j.jpeds.2012.02.003

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  6 in total

Review 1.  New-generation intravenous fat emulsions and bronchopulmonary dysplasia in preterm infants: a systematic review and meta-analysis.

Authors:  Xue Fan; Ying Tang; Jun Tang; Juan Chen; Jing Shi; Hua Wang; Bin Xia; Yi Qu; Dezhi Mu
Journal:  J Perinatol       Date:  2020-07-07       Impact factor: 2.521

Review 2.  Emerging Clinical Benefits of New-Generation Fat Emulsions in Preterm Neonates.

Authors:  Gregory Guthrie; Muralidhar Premkumar; Douglas G Burrin
Journal:  Nutr Clin Pract       Date:  2017-01-27       Impact factor: 3.080

3.  Risks and benefits of prophylactic cyclic parenteral nutrition in surgical neonates.

Authors:  T Hang Nghiem-Rao; Laura D Cassidy; Elizabeth M Polzin; Casey M Calkins; Marjorie J Arca; Praveen S Goday
Journal:  Nutr Clin Pract       Date:  2013-10-09       Impact factor: 3.080

4.  Eligibility Criteria and Representativeness of Randomized Clinical Trials That Include Infants Born Extremely Premature: A Systematic Review.

Authors:  Leeann R Pavlek; Brian K Rivera; Charles V Smith; Joanie Randle; Cory Hanlon; Kristi Small; Edward F Bell; Matthew A Rysavy; Sara Conroy; Carl H Backes
Journal:  J Pediatr       Date:  2021-04-21       Impact factor: 6.314

Review 5.  Prevention and Treatment of Intestinal Failure-Associated Liver Disease in Children.

Authors:  Lorenzo Norsa; Emanuele Nicastro; Angelo Di Giorgio; Florence Lacaille; Lorenzo D'Antiga
Journal:  Nutrients       Date:  2018-05-24       Impact factor: 5.717

6.  Correlation between mutation of MDR3 gene exon 6 and parenteral nutrition-associated cholestasis of preterm infants.

Authors:  Xiu Fang Yang; Guo Sheng Liu; Bing Yi
Journal:  Exp Ther Med       Date:  2014-09-19       Impact factor: 2.447

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.